The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC.
Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME).
Seekyo’s lead compound SKY01 induces a selective tumor self-destruction:
• Efficacy and safety validated in small and large animals (e.g. Dogs).
• Unprecedented antitumor efficacy vs. Standards of Care
• Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal…)
• Low Cost of Goods
Company Details
- Employees
- 7
- Founded
- -
- Address
- 2 Av Galilée, Futuroscope,france
- co****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- seekyo-therapeutics.com
- Keywords
- Therapeutic vectors, ADC, Microenvironment, Cancer, Oncology, Therapeutic vector, Smart Molecular System, Drug Delivery System, in vitro, in vivo, Life Science, Biotechnology, Chemotherapy, Cancer treatment, Innovation, breaking through, breaking through technology, Molecular platform, Treatment side effects, Cancer side effects, Adverse effects, Chemotherapy adverse effects.
- HQ
- Futuroscope
Seekyo Therapeutics Questions
Seekyo Therapeutics's website is seekyo-therapeutics.com
Seekyo Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/seekyo
Seekyo Therapeutics has
7 employees.
View email and phone details for 7
employees at Seekyo Therapeutics.
Seekyo Therapeutics's industry is
Biotechnology Research
Seekyo Therapeutics's top competitors are
Carla Biotherapeutics,
Neolys Diagnostics,
Landmark Bioventures Ag,
Persea,
Starkage Therapeutics,
Entreprises En Vienne,
Medetia Pharmaceuticals,
Basilea Pharmaceutica,
Beams,
Oncodesign Precision Medicine - Opm.
Seekyo Therapeutics's support email address is contact@seekyo-therapeutics.com
Seekyo Therapeutics's categories are Biotechnology Research
Seekyo Therapeutics's founding year is 2018
